Cancers 2010, 2(3), 1683-1688; doi:10.3390/cancers2031683
Review

Epigenetic Therapy in Human Choriocarcinoma

Noriyuki Takai 1,* email and Hisashi Narahara 2 email
1 Department of Obstetrics and Gynecology, Oita University Faculty of Medicine, Oita, Japan 2 Department of Obstetrics and Gynecology, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-machi, Yufu-shi, Oita 879-5593, Japan
* Author to whom correspondence should be addressed.
Received: 18 August 2010; in revised form: 3 September 2010 / Accepted: 9 September 2010 / Published: 10 September 2010
(This article belongs to the Special Issue Epigenetics of Cancer Progression)
PDF Full-text Download PDF Full-Text [114 KB, uploaded 10 September 2010 09:00 CEST]
Abstract: Because epigenetic alterations are believed to be involved in the repression of tumor suppressor genes and promotion of tumorigenesis in choriocarcinomas, novel compounds endowed with a histone deacetylase (HDAC) inhibitory activity are an attractive therapeutic approach. HDAC inhibitors (HDACIs) were able to mediate inhibition of cell growth, cell cycle arrest, apoptosis, and the expression of genes related to the malignant phenotype in choriocarcinoma cell lines. In this review, we discuss the biologic and therapeutic effects of HDACIs in treating choriocarcinoma, with a special focus on preclinical studies.
Keywords: choriocarcinoma; epigenetics; histone deacetylase inhibitors

Article Statistics

Click here to load and display the download statistics.

Cite This Article

MDPI and ACS Style

Takai, N.; Narahara, H. Epigenetic Therapy in Human Choriocarcinoma. Cancers 2010, 2, 1683-1688.

AMA Style

Takai N, Narahara H. Epigenetic Therapy in Human Choriocarcinoma. Cancers. 2010; 2(3):1683-1688.

Chicago/Turabian Style

Takai, Noriyuki; Narahara, Hisashi. 2010. "Epigenetic Therapy in Human Choriocarcinoma." Cancers 2, no. 3: 1683-1688.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert